Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2020 Nov 19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Endocrinologica 2020 Nov 19

DOI: 10.23736/S0391-1977.20.03342-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Personalized treatment for thyroid cancer: current data and new perspectives

Carla COLOMBO 1, 2 , Noemi GIANCOLA 1, Laura FUGAZZOLA 1, 2

1 Division of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy; 2 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy


PDF


More conservative and personalized treatment options have been developed in recent years to face the rising diagnosis of low-risk differentiated thyroid carcinoma (DTC). The present review describes the changes in the direction toward a more risk-adapted management either in the treatment or in the follow-up of DTC. Particular attention is given to the innovations introduced by the latest guidelines for low-risk tumors, starting from the most appropriate extension of surgery up to the post-operative management. The emerging role of active surveillance for lowrisk microcarcinoma is discussed, as well as the development of percutaneous strategies in the setting of malignant thyroid disease. The recent use of approved new systemic target therapies for advanced radioiodine refractory thyroid cancer is reported, together with the description of new compounds in trial. Finally, we provide some considerations to improve the risk evaluation in a pre-surgical setting, especially related to the rising role of genetics, in order to enable better risk-based cancer management and personalized treatment choice.


KEY WORDS: Thyroid cancer; Lobectomy; RAI; Active surveillance; TKI

top of page